Literature DB >> 6168845

N"-Cyano-N-4-pyridyl-N'-1,2,2-trimethyl-propylguanidine, a new vasodilating agent: acute effect of blood pressure and pharmacokinetics in hypertensive patients.

T Kardel, T Hilden, J Carlsen, J Trap-Jensen.   

Abstract

N"-Cyano-N-4-pyridyl-N'-1,2,2-trimethylpropylguanidine (P 1134) is a new vasodilating antihypertensive compound. In an open study, P 1134 was given in single oral doses of from 10 to 25 mg to 12 previously untreated patients with essential hypertension. All patients responded with decreases in mean arterial pressure (MAP) of at least 10 mm Hg and with almost equal blood pressure decreases in the supine and erect position. The increase of dose was significantly correlated with a progressive reduction of blood pressure. At a dose of 25 mg, the maximal decrease in supine MAP averaged 38 mm Hg, and the maximal increase in heart rate averaged 23 beats/min. Peak effect and serum concentration were seen about 1 h after tablet intake. The serum half-life from the peak concentration averaged 2.5 h. It is concluded that P 1134 is a fast-acting, effective antihypertensive agent.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6168845     DOI: 10.1097/00005344-198109000-00010

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  12 in total

Review 1.  Pinacidil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of hypertension.

Authors:  H A Friedel; R N Brogden
Journal:  Drugs       Date:  1990-06       Impact factor: 9.546

2.  Long term haemodynamic effects of pinacidil and hydralazine in arterial hypertension.

Authors:  J E Carlsen; H A Jensen; M Rehling; J O Lund; J Trap-Jensen
Journal:  Drugs       Date:  1988       Impact factor: 9.546

3.  The effects of long-acting pinacidil on intra-arterial blood pressure.

Authors:  M P Caruana; I Al-Khawaja; P Royston; E B Raftery
Journal:  Br J Clin Pharmacol       Date:  1985-08       Impact factor: 4.335

4.  Treatment of essential hypertension and hypertension associated with renal impairment with pinacidil: a new vasodilator.

Authors:  E G Breen; D Mulhall; J A Keogh
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

5.  Arterial vasodilating profile and biological effects of pinacidil in healthy volunteers.

Authors:  C Thuillez; E Pussard; E Bellissant; C Richer; R Kechrid; J F Giudicelli
Journal:  Br J Clin Pharmacol       Date:  1991-01       Impact factor: 4.335

6.  Effect of pinacidil on blood pressure, plasma catecholamines and plasma renin activity in essential hypertension.

Authors:  G Muiesan; R Fariello; M L Muiesan; O E Christensen
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

7.  Acute haemodynamic effects of pinacidil in man.

Authors:  D P Nicholls; J G Murtagh; M E Scott; P Morton; R G Shanks
Journal:  Br J Clin Pharmacol       Date:  1986-09       Impact factor: 4.335

8.  Pharmacokinetics and hypotensive effect in healthy volunteers of pinacidil, a new potent vasodilator.

Authors:  J W Ward; A McBurney; P R Farrow; P Sharp
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

9.  Pinacidil, a new vasodilator, in the treatment of mild to moderate essential hypertension.

Authors:  V D'Arcy; M Laher; D McCoy; P Sullivan; C H Walsh; M P Hickey
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

10.  Pinacidil, a new vasodilator: pharmacokinetics and pharmacodynamics of a new retarded release tablet in essential hypertension.

Authors:  J E Carlsen; T Kardel; H A Jensen; M Tangø; J Trap-Jensen
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.